Navigation Links
Esperion Announces Results From Phase 1 Study and Four Preclinical Studies for ETC-1002
Date:5/2/2011

PLYMOUTH, Mich., May 2, 2011 /PRNewswire/ -- Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the results from a Phase 1 study and four preclinical studies for ETC-1002 at the Arteriosclerosis, Thrombosis and Vascular Biology 2011 Scientific Sessions in Chicago.  In the Phase 1 study, treatment with ETC-1002 was shown to be safe and well tolerated and to significantly reduce LDL-C levels in subjects with mild dyslipidemia.

ETC-1002, the company's lead product candidate, is a novel small molecule that has demonstrated preclinical and clinical activity as a metabolic regulator of imbalances in lipid and carbohydrate metabolism.  It is being developed to treat dyslipidemia and other cardio-metabolic risk factors.  Mechanistic studies indicate that treatment with ETC-1002 increases AMP-kinase phosphorylation, inhibits fatty acid and cholesterol synthesis and also enhances fatty acid oxidation.   In the Phase 1 study, treatment with ETC-1002 resulted in consistent, dose-related reductions in LDL-C.  The randomized, double-blind, placebo-controlled study included 32 subjects treated with daily doses of ETC-1002 up to 120 mg or placebo for 14 days and 21 subjects treated with 120 mg of ETC-1002 or placebo for 28 days.

"Cardio-metabolic diseases remain the number one cause of death in people around the world, and research indicates that an effective agent to manage both plasma lipids and glucose could offer significant benefit to millions of patients.  The results of our Phase 1 study show a statistically significant lowering of LDL-C in mildly dyslipidemic subjects and a favorable safety profile, and serve as a solid foundation for clinical evaluation in patients with other cardio-metabolic abnormalities," said Roger Newton, PhD, President and CEO of Esperion.

In addition to the result
'/>"/>

SOURCE Esperion Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC-1002
2. TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics
3. Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
4. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
5. Samplify Systems Announces Availability of Prism FP Floating Point Compression
6. Vertical Health Solutions to Begin Doing Business as OnPoint Medical Diagnostics and Announces Completion of Symbol Change
7. ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011
8. BioMarin Announces First Quarter 2011 Financial Results
9. IRIDEX Announces First Quarter 2011 Conference Call and Release Date
10. Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 13th International Myeloma Workshop
11. OncoMed Pharmaceuticals Announces FDA Clearance to Commence Phase 1 Testing of Anti-Cancer Stem Cell Therapeutic OMP-18R5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Research and Markets has announced the ... Diagnostic Tests, 9th Edition" report to their offering. ... clinical testing market and all of its segments, providing customers ... Companies For Business Planning. This is the ninth ... of 2013 and early 2014. New entrants, new technologies have ...
(Date:9/15/2014)... , Sept. 15, 2014  MedExpress Urgent Care, a national ... now offering flu shots for ages four and up at ... patients to get their flu shot early. ... the end of June, making late summer and early fall ... season. MedExpress Vice President of Provider and Clinical Quality, ...
(Date:9/15/2014)... CITY , Sept. 15, 2014 /PRNewswire-iReach/ -- ... invasive surgical (MIS) visualization products, is pleased to ... for its quality management system (QMS) through BSI, ... important step in Olive Medical complying with all ... devices.  It is the goal of Olive Medical ...
Breaking Medicine Technology:The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition 2The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition 3MedExpress Quotes Late Summer, Early Fall As Best Time to Receive Flu Shot 2Olive Medical Achieves ISO 13485:2003 Certification 2
... Assured Pharmacy (Pink Sheets: APHY ), a ... sufferers of chronic pain announced that total sales on a ... $1,422,163 which equates to $67,722 per business day .  This ... of $1,402,374 for June 2010 and an increase of 6.2 ...
... Novavax, Inc. (Nasdaq: NVAX ) President and CEO ... Health and Human Services Secretary Kathleen Sebelius and other public ... development of drugs and vaccines to prevent the spread of ... the plan,s five key initiatives: Define and ...
Cached Medicine Technology:Assured Pharmacy Reports Same Store Sales for the Month of July 2010 2Assured Pharmacy Reports Same Store Sales for the Month of July 2010 3NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures 2NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures 3
(Date:9/15/2014)... New York (PRWEB) September 15, 2014 ... Bard, Inc. continue to move forward in the federal ... District of West Virginia, Bernstein Liebhard LLP reports. According ... a Final Order on September 10th that provides for ... Order notes that none of the affected plaintiffs has ...
(Date:9/15/2014)... large cohort analysis from the prospective Prostate, Lung, Colorectal ... who had moderate baldness affecting both the front and ... at a 40% increased risk of developing aggressive prostate ... poorer prognosis relative to non-aggressive prostate cancer) later in ... no significant link between other patterns of baldness and ...
(Date:9/15/2014)... The White House has recently begun shifting ... jail and prison and toward helping them access addiction ... positive change. , The nation is currently grappling with ... to an article from The Washington Post , ... away from using the criminal justice system to address ...
(Date:9/15/2014)... By Maureen Salamon ... (HealthDay News) -- Pediatricians prescribe antibiotics about twice as ... and throat infections, a new study indicates. More ... children and teens may be unnecessary, according to researchers ... excess antibiotic use not only fails to eradicate children,s ...
(Date:9/15/2014)... shown that certain brain regions are associated with ... decision-making. , How and where these specific abilities ... cognition is still under investigation. However, researchers at ... St. Louis, Missouri, believe that several hub regions ... function as an integrated network. , In research ...
Breaking Medicine News(10 mins):Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:Certain form of baldness at age 45 linked to higher risk of aggressive prostate cancer 2Health News:White House Shifts Policy on Drugs 2Health News:Kids Prescribed Antibiotics Twice as Often as Needed, Study Finds 2Health News:Kids Prescribed Antibiotics Twice as Often as Needed, Study Finds 3Health News:Network measures predict neuropsychological outcome after brain injury 2
... its new patient-education website, www.CLIclinicalstudy.com , is now “live”. ... enrolling in the Company’s clinical trial and their referring physicians ... underlies it, and the location of the study’s sites. ... ...
... help consumers get,accurate, dependable information about healthcare ... support consumer,engagement and improved quality in healthcare, ... consumer-focused, internet-based public,reporting. These guidelines will assist ... in an evidence-based and,consumer-friendly format that can ...
... (October 26, 2008) A single administration of a novel, ... that were more than 20 times higher than those ... according to a study by NanoBio Corporation. The new ... produce this effect. , Results of the study are ...
... blood that was 29 days or older faced twice the ... who receive a transfusion of stored blood that is 29 ... or more serious infections compared to those who get "fresher" ... that current U.S. regulations set the upper limit for blood ...
... of candy, ST. LOUIS, Oct. 28 The ... year, and a sizeable portion of that indulgence,is eaten ... will,simply create an expanded beltline. However, for the more ... can pose more,tricky consequences., To help ease candy ...
... Resources to Prevent Millions in Lost Wages, SAN ... of the flu are reported annually, financially challenging working,families ... days. QuickHealth meets,the challenge by providing updated information and ... to clarify treatment options and to help,them make better ...
Cached Medicine News:Health News: Harvest Technologies Announces Patient Education Website, www.CLIclinicalstudy.com : Supports first randomized, placebo-controlled clinical trial in the U.S. using autologous adult stem cells to treat patients with end-stage Critical Limb Ischemia 2Health News:NQF Endorses Guidelines for Consumer-Focused Public Reporting 2Health News:NQF Endorses Guidelines for Consumer-Focused Public Reporting 3Health News:NQF Endorses Guidelines for Consumer-Focused Public Reporting 4Health News:NQF Endorses Guidelines for Consumer-Focused Public Reporting 5Health News:New intranasal influenza vaccine triggers robust immunity with significantly less antigen 2Health News:Older Blood Boosts Chances of Infection in Transfusion Patients 2Health News:Older Blood Boosts Chances of Infection in Transfusion Patients 3Health News:Orthodontists Offer Sweet Incentives for Tricky Halloween Treats 2Health News:Orthodontists Offer Sweet Incentives for Tricky Halloween Treats 3Health News:75 Million Missed Work Days Expected This Flu Season 2Health News:75 Million Missed Work Days Expected This Flu Season 3
... an ultra-capacity bacterial growth system, combines ... a high-capacity format for bacterial growth. ... with Bioneer's HT-Prep™ Automatic DNA Extractor. ... advantages over traditional floor shakers. Plate-holding ...
Inquire...
... Refrigerated incubators,Two refrigerated incubators ... life and life cycle,testing. Microprocessor ... digital temperature display. High/low audible ... contacts. Additional internal chamber safety ...
Inquire...
Medicine Products: